Clinical Trial Results:
Multicenter, randomized, open label study evaluating an anti Insulin-like Growth Factor-1 Receptor (IGF-1R/CD221) monoclonal antibody, AVE1642, administered every 4 weeks in combination with fulvestrant (Faslodex®) in postmenopausal patients with advanced hormono-dependent breast cancer
Summary
|
|
EudraCT number |
2008-000810-54 |
Trial protocol |
FR ES IT |
Global completion date |
10 Nov 2010
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
27 Feb 2016
|
First version publication date |
27 Feb 2016
|
Other versions |
|
Summary report(s) |
TCD10631 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.